National Institutes of Health (NIH)
169 articles with National Institutes of Health (NIH)
The U.S. National Institutes of Health (NIH) is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
Ellume Secures $30M from National Institutes of Health RADx Initiative to Accelerate Development of Rapid COVID-19 DiagnosticsThe company will launch three rapid COVID-19 testing products in the U.S.
Ellume , the company reimagining digital diagnostics, today announced a $30 million Phase 2 award from the U.S. National Institutes of Health (NIH)’s Rapid Acceleration of Diagnostics (RADx) initiative to accelerate the clinical testing and manufacturing of three COVID-19 antigen tests. The RADx initiative rigorously reviews and selects innovative, highly accurate diagnostic technologies to move quickly through the development pipeline t
The U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the COVID-19 pandemic.
Funding will enable expansion of automated Bioworks facility for large scale suppression testing using next generation sequencing
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
Andor Health Platform to Accelerate Clinical Research Team Collaboration and Communication at National Institutes of Health
Andor Health's ThinkAndor™ platform to push critical notifications to NIH Clinical Center teams, providers and patients, while increasing overall operational efficiency
3/23/2020Here's a look at some of last week's clinical trial news.
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
The focus of the research will be to learn more about ApoE4 and how and why it affects Alzheimer’s disease.
Windgap Medical and University of Minnesota Twin Cities Receive $3.2 Million NIH Grant to Develop Cyanide Antidote Autoinjector
Under the grant, researchers from the University's Center for Drug Design, College of Pharmacy, and Massachusetts-based pharmaceutical company Windgap Medical are collaborating to design an autoinjector.
Instead of injecting the vaccine into the muscle or skin, researchers injected BCG directly into the bloodstream. The results were dramatically improved effectiveness.
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.
CorTechs Labs Enters Phase 2 of $1.15 Million NIH Grant to Automate the Diagnosis and Prediction of Alzheimer’s Disease
Phase two of this grant proves CorTechs Labs’ PETQuant™ to be clinically and commercially viable
The Injectrode™ cures inside the body and is molded to the shape of the specific target.
EicOsis Awarded SBIR Grant from the NCI/NIH to Evaluate the Potential of Drug Candidate, EC5026, to Treat Cancer-associated Pain
EC5026 is an orally active potent small molecule that has been shown to be highly efficacious for pain relief of both inflammatory and neuropathic pain in a variety of animal species.
Molecular Targeting Technologies, Inc. Receives Global Rights From NIH for Integrin-Targeting Radiotherapeutics to Treat GBM and Lung Cancer
The key feature of this technology is the incorporation of a derivative of Evans Blue into RGD peptide radiopharmaceutical which binds to both albumin and integrin thus extends residence time, enabling smaller and less frequent dosing.
The organizations hope the funding will result in clinical trials in the U.S. and countries in sub-Saharan Africa in the next seven to 10 years. Francis Collins, director of the NIH, said they would focus on “access, scalability and affordability.”
The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health
Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies
ANS-6637, which is in Phase 2 clinical development, is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders.
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
Rafael will provide the compound for the study.